healthcare

Is the Sage Therapeutics Implosion Overblown?

Posted: December 6, 2019 at 11:25 am

Sage Therapeutics Inc. (NASDAQ: SAGE) shareholders took a bath on Thursday after results from its late-stage major depressive disorder (MDD) trial came public. Despite shares getting more than halved in ...
Read Full Story »

Thursday’s Biggest Biotech Movers

Posted: December 5, 2019 at 11:20 am

Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff. The biotechnology sector is pushing near all-time highs, and ...
Read Full Story »

Why This Transfusion-Dependent Beta-Thalassemia Trial Is Taking Off

Posted: December 4, 2019 at 12:00 pm

Protagonist Therapeutics Inc. (NASDAQ: PTGX) shares jumped on Wednesday after the company announced preliminary results from its midstage study for patients with transfusion-dependent beta-thalassemia. Specifically, the results come from the ...
Read Full Story »

Are Audentes Shareholders Getting Enough in the Acquisition?

Posted: December 3, 2019 at 12:10 pm

Audentes Therapeutics Inc. (NASDAQ: BOLD) shares more than doubled on Tuesday after the firm announced that it would be acquired by Astellas. Although Audentes has only been public for just ...
Read Full Story »

How Aslan Pharma Is Capitalizing on Its Huge Atopic Dermatitis Success

Posted: December 3, 2019 at 11:40 am

Aslan Pharmaceuticals Ltd. (NASDAQ: ASLN) has been on a roller coaster for the past two weeks. Shares were less than $0.50 apiece in November, and only yesterday shares peaked at ...
Read Full Story »

Why Mixed Results From This Chronic Kidney Disease Study Aren’t That Great

Posted: December 3, 2019 at 10:05 am

Cara Therapeutics Inc. (NASDAQ: CARA) shares were crushed on Tuesday after the firm announced results from its midstage trial in patients with chronic kidney disease. Specifically, the results come from ...
Read Full Story »

Why Investors Shouldn’t Sleep on This Narcolepsy Study

Posted: December 3, 2019 at 9:40 am

Axsome Therapeutics Inc. (NASDAQ: AXSM) shares jumped early on Tuesday after the firm announced positive results from its midstage narcolepsy trial. Specifically, the results come from the Phase 2 Concert ...
Read Full Story »

Why This Atopic Dermatitis Study Was So Well Received

Posted: December 2, 2019 at 10:15 am

Aslan Pharmaceuticals Ltd. (NASDAQ: ASLN) shares jumped on Monday after the firm announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of ASLAN004 ...
Read Full Story »

Why This Seizure Treatment Could Be the Next Big Thing

Posted: December 2, 2019 at 9:40 am

Aquestive Therapeutics Inc. (NASDAQ: AQST) shares jumped early on Monday after the firm announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food ...
Read Full Story »

Major Biopharma Catalysts on the December FDA Calendar

Posted: November 29, 2019 at 10:40 am

Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with ...
Read Full Story »

Big Pharma Short Sellers Hike Their Bets

Posted: November 27, 2019 at 9:00 am

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Run For Cover From Major Biotechs

Posted: November 27, 2019 at 8:40 am

The short interest data are out for the most recent settlement date, November 15. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

What This Study For ANCA Vasculitis Means Going Forward

Posted: November 26, 2019 at 12:21 pm

ChemoCentryx, Inc. (NASDAQ: CCXI) shares more than tripled on Tuesday after the firm, in conjunction with Vifor Fresenius Medical Care Renal Pharma, announced positive topline data from its late-stage trial ...
Read Full Story »

Why This Newly FDA Approved Sickle Cell Treatment Will Be Huge

Posted: November 26, 2019 at 11:02 am

Global Blood Therapeutics, Inc. (NASDAQ: GBT) shares jumped on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta (voxelotor) tablets ...
Read Full Story »

Novartis Finally Comes Through With Its Acquisition of Medicines Co

Posted: November 25, 2019 at 10:02 am

Medicines Co. (NASDAQ: MDCO) shares shot up on Monday after it was reported that Novartis A.G. (NYSE: NVS) will be acquiring the firm. The transaction was unanimously approved by the ...
Read Full Story »